JNJ and REGN Related Headlines
Go Back- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
- Trump to announce prescription drug price agreements
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Buy this U.S. large-cap biopharma stock: JPMorgan
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports
